Drug Profile
Fenebrutinib - Genentech
Alternative Names: GDC-0853; RG-7845; RO-7010939Latest Information Update: 01 Dec 2023
Price :
$50
*
At a glance
- Originator Genentech
- Developer Chugai Pharmaceutical; Genentech
- Class Antineoplastics; Antirheumatics; Piperazines; Pyrazines; Pyridines; Skin disorder therapies; Small molecules
- Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Multiple sclerosis
- No development reported Autoimmune disorders
- Discontinued Chronic lymphocytic leukaemia; Chronic urticaria; Non-Hodgkin's lymphoma; Rheumatoid arthritis; Systemic lupus erythematosus
Most Recent Events
- 13 Oct 2023 Efficacy and adverse events data from phase III FENopta trial in Multiple sclerosis released by Genentech
- 11 Oct 2023 Efficacy data from phase III FENopta trial in Multiple sclerosis presented at the 9th Triennial joint meeting of Americas Committee for Treatment and Research in Multiple Sclerosis and the European Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS-2023)
- 11 Oct 2023 Pharmacodynamics data from preclinical studies in Multiple sclerosis presented at the 9th Triennial joint meeting of Americas Committee for Treatment and Research in Multiple Sclerosis and the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS-ACTRIMS-2023)